Monthly research recap
Depression research: August 2026
What August 2026's 11 new studies found, synthesized from the papers below. All Depression research →
The synthesis
Synthesized from 11 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Depression, major depressive disorder, MDD, depressive disorder, treatment-resistant depression, then ranked by relevance.
In August 2026, depression research focused on ketamine/esketamine and psilocybin for treatment-resistant depression, with consistent evidence of rapid and significant antidepressant effects, though comparative safety signals for esketamine (e.g., higher cardiac arrest risk) and durability of effects remain key caveats. A meta-analysis of psilocybin RCTs found large short-term effects, and a large target trial emulation suggested esketamine may carry higher risks of certain adverse outcomes than injectable ketamine. Overall, findings are consistent in supporting these rapid-acting treatments, but long-term efficacy and safety, especially in real-world populations, are not fully established.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Clinical correlates of anhedonia non-response to ketamine in treatment-resistant depression. 2026 | retrospective analysis of naturalistic, observational registries | 34 | Mixed | Anhedonia non-response to short-term ketamine was associated with single marital status, fewer lifetime depressive episodes, and lower rates of substance use disorder, with no significant differences in most clinical features. |
| The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis. 2026 | observational cohort with correlation and path analysis | 79 | Supports | Therapeutic alliance facilitated the psychedelic experience, but the psychedelic experience itself had stronger direct effects on depression outcomes than the alliance. |
| (2R,6R)-HNK improved LPS-induced depression-like behavior by inhibiting Vcam1/Caspase-1/IL-1β pathway. 2026 | experimental study | Supports | (2R,6R)-HNK attenuated LPS-induced neuronal pyroptosis and neuroinflammation and ameliorated depression-like behavior in mice partially by downregulating the Vcam1/caspase-1/IL-1β pathway. | |
| Brain iron-sensitive markers (magnetic susceptibility and R2*) predict antidepressant response to ketamine in treatment-resistant depression. 2026 | double-blind, randomized placebo-controlled trial followed by an extended single-arm open-label study | 17 | Supports | Baseline magnetic susceptibility in the right nucleus accumbens and R2* in the left amygdala predicted antidepressant effects of repeated ketamine infusions in patients with treatment-resistant depression. |
| Faster and greater antidepressant response to intravenous ketamine in bipolar compared with unipolar treatment-resistant depression: Diagnostic and sex-related findings from a naturalistic study. 2026 | observational study | 97 | Supports | Intravenous ketamine produced faster and greater antidepressant effects in bipolar depression compared with unipolar depression, with no sex differences in efficacy. |
| Role of concomitant benzodiazepines, lithium, and lamotrigine in modulating the antidepressant effects of subcutaneous esketamine in patients with treatment-resistant depressive episodes: A retrospective naturalistic study. 2026 | observational cohort | 178 | Mixed | Concomitant benzodiazepine use was associated with higher depressive symptom severity during subcutaneous esketamine treatment, while lamotrigine and lithium showed no significant association with outcomes. |
| Comparative effectiveness and safety of esketamine versus injectable racemic ketamine and oral antidepressants for major depressive disorder: A population-based target trial emulation. 2026 | emulated target trial using observational data | 1089419 | Mixed | Esketamine was associated with higher risks of suicidal ideation, generalized anxiety disorder, insomnia, and cardiac arrest compared with injectable ketamine, but lower risks of suicidal ideation, suicide attempt, and generalized anxiety disorder compared with oral antidepressants, although with a higher risk of cardiac arrest. |
| Network dysregulation in depression: A synthesis of HPA Axis, BDNF signaling, and neurotransmitter interactions across multidimensional systems. 2026 | review | Supports | Argues that the BDNF/CREB signaling pathway serves as a core hub mediating multisystem network dysfunction in depression, integrating emotional-cognitive circuits, HPA axis activity, neurotransmitter systems, and neuroplasticity. | |
| Ketamine for Depression in Serious Illness: Evidence, Safety, and Practical Approaches. 2026 | review | Supports | Argues that ketamine and esketamine provide the strongest evidence among rapid-acting antidepressants and may be preferred when urgent symptom relief is needed, but rigorous psychiatric trials in serious illness are lacking. | |
| Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis. 2026 | systematic review and meta-analysis | Supports | Standard-dose psilocybin was superior to control in reducing depressive symptoms and produced higher response and remission rates at 2-3 weeks and 6-12 weeks post-treatment, with lower all-cause discontinuation, though it was associated with transient headaches and nausea. | |
| Combining Mindfulness-Based Cognitive Therapy With Escitalopram for Cognitive and Emotional Recovery in Older Adults With Treatment-Resistant Depression. 2026 | randomized controlled trial | 230 | Supports | Adding MBCT to escitalopram hydrobromide significantly improved cognitive function, reduced depressive symptoms, and enhanced quality of life in older adults with TRD compared to escitalopram alone. |
Points of agreement
- Ketamine and esketamine show rapid and significant antidepressant effects in treatment-resistant depression across multiple studies.
- Psilocybin at standard doses is effective for major depressive disorder in the short term, with higher response and remission rates than control.
- Therapeutic alliance and psychedelic experience both contribute to psilocybin's antidepressant effects, but the psychedelic experience itself is more strongly associated with outcomes.
- Combining psychological therapy (MBCT) with medication enhances outcomes in older adults with treatment-resistant depression.
Conflicts
- Esketamine was associated with higher risks of suicidal ideation and cardiac arrest compared with injectable ketamine, but lower risks of suicidal ideation and suicide attempt compared with oral antidepressants.
- One study found no significant differences in most clinical features between anhedonia responders and non-responders to ketamine, while another found baseline brain iron markers predicted response.
- The meta-analysis of psilocybin found large effects, but a post hoc analysis suggested the psychedelic experience itself, not the alliance, drives outcomes, which may conflict with the emphasis on therapy in psilocybin-assisted treatment.
Gaps
- Long-term durability of antidepressant effects beyond 12 weeks is not well established for ketamine, esketamine, and psilocybin.
- Comparative safety of esketamine versus other treatments, especially cardiac arrest risk, needs further investigation in prospective studies.
- Evidence for ketamine/esketamine in serious illness is limited to small open-label studies and perioperative trials.
- Predictors of response (e.g., brain iron markers, clinical features) require replication in larger samples.
- The role of concomitant medications (e.g., benzodiazepines) in modulating esketamine outcomes needs confirmation in controlled trials.
- Most studies focus on short-term outcomes; maintenance dosing and long-term management are not addressed.